BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Malaria In vitro , cell culture and mouse studies identified asparagine ethylenediamine-based inhibitors of Plasmodium falciparum proteasome subunit β type 5 that could help treat malarial infection. Screening of a library of tool compound proteasome...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Malaria Cell culture and mouse studies identified an inhibitor of P. falciparum proteasome subunit β type 2 and proteasome subunit β type 5 that could help treat malaria. Chemical synthesis and testing of vinyl...
BioCentury | Sep 23, 2017
Emerging Company Profile

Selective suppression

Kezar Life Sciences Inc. is targeting the immunoproteasome to selectively suppress the hyperactive immune cells that drive autoimmunity. The company expects its biologics to have the rapid onset and broad activity of steroids, but without...
BioCentury | Jan 11, 2017
Distillery Therapeutics


INDICATION: Graft rejection; heart transplant rejection Mouse studies identified a dipeptide inhibitor of PSMB8 that could help prevent skin and heart transplant rejection. Chemical synthesis and testing in in vitro activity assays of dipeptides yielded...
BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Proteasome subunit β2 (PSMB2)

...Cancer INDICATION: Breast cancer; multiple myeloma (MM); cancer In vitro and mouse studies identified a PSMB2...
...and in vitro testing of quinoline-sulfonyl analogs identified a compound ( VR23 ) that inhibited PSMB2...
...the compound in Phase III testing to treat B cell lymphoma. TARGET/MARKER/PATHWAY: Proteasome subunit β2 (PSMB2...
BioCentury | Jun 5, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Proteasome subunit-b type 4 (PSMB4); serine hydroxymethyltransferase 2 mitochondrial (SHMT2) In vitro and mouse studies suggest inhibiting PSMB4 or SHMT2 could help treat cancer....
BioCentury | Apr 15, 2013

De-risking money

De-risking money Cleave Bioscience Inc. 's investors allowed New Enterprise Associates to add $10 million last week on the same terms as a 2011 A round because the lion's share of money and de-risking is...
BioCentury | Mar 25, 2013
Emerging Company Profile

Cleave: Proteasome alternatives

Cleave Biosciences Inc. is developing small molecules against new targets that regulate protein homeostasis. The compounds could offer better bioavailability than existing proteasome inhibitors and work in a wider range of cancers, including solid tumors....
Items per page:
1 - 10 of 15